Fumio Nishikaku
Direktor/Vorstandsmitglied bei HuLA immune, Inc.
Aktive Positionen von Fumio Nishikaku
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
HuLA immune, Inc.
HuLA immune, Inc. Pharmaceuticals: MajorHealth Technology HuLA immune, Inc. is a Japanese company that provides immune cell therapy for cancer treatment. The company is based in Tokyo, Japan. The text in the company's description appears to be a mix of non-English languages, including British English and Japanese. It was founded in 2017 and the CEO is Yasuhiro Shindo. | Direktor/Vorstandsmitglied | - | - |
MATRIXOME, Inc.
MATRIXOME, Inc. Miscellaneous Commercial ServicesCommercial Services MATRIXOME, Inc. is a Japanese regenerative medicine company founded in 2015. The company is based in Osaka, Japan and develops regenerative medicine using laminin E8 fragment technology. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Fumio Nishikaku
Statistik
International
Japan | 3 |
Operativ
Director/Board Member | 2 |
Sektoral
Health Technology | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
HuLA immune, Inc.
HuLA immune, Inc. Pharmaceuticals: MajorHealth Technology HuLA immune, Inc. is a Japanese company that provides immune cell therapy for cancer treatment. The company is based in Tokyo, Japan. The text in the company's description appears to be a mix of non-English languages, including British English and Japanese. It was founded in 2017 and the CEO is Yasuhiro Shindo. | Health Technology |
MATRIXOME, Inc.
MATRIXOME, Inc. Miscellaneous Commercial ServicesCommercial Services MATRIXOME, Inc. is a Japanese regenerative medicine company founded in 2015. The company is based in Osaka, Japan and develops regenerative medicine using laminin E8 fragment technology. | Commercial Services |
- Börse
- Insiders
- Fumio Nishikaku
- Erfahrung